Результаты поиска

New understanding of the damage of SARS-CoV-2 infection outside the respiratory system.

Since early December 2019, a number of pneumonia cases associated with unknown coronavirus infection were identified in Wuhan, China, and many additional cases were identified in other regions of China and in other countries within 3 months. Currently, more than 80,000 cases have been diagnosed in China, including more than 3000 deaths. The epidemic is spreading to the rest of the world, posing a grave challenge to prevention and control. On February 12, 2020, the International Committee on Taxonomy of Viruses and the World Health Organization officially named the novel coronavirus and associa

B cell lineage reconstitution underlies CAR-T cell therapeutic efficacy in patients with refractory myasthenia gravis.

B-cell maturation antigen (BCMA), expressed in plasmablasts and plasma cells, could serve as a promising therapeutic target for autoimmune diseases. We reported here chimeric antigen receptor (CAR) T cells targeting BCMA in two patients with highly relapsed and refractory myasthenia gravis (one with AChR-IgG, and one with MuSk-IgG). Both patients exhibited favorable safety profiles and persistent clinical improvements over 18 months. Reconstitution of B-cell lineages with sustained reduced pathogenic autoantibodies might underlie the therapeutic efficacy. To identify the possible mechanisms un

Abstracts from the 53rd European Society of Human Genetics (ESHG) Conference: e-Posters.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Abstracts of the 12th European Cytogenomics Conference 2019 : Salzburg, Austria. 6-9 July 2019

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Предлагаемый рабочий поток для тщательного анализа бактериальных стенограмм в данных RNAseq из внеклеточных везеиклов.

ВВЕДЕНИЕ: Микробиота однозначно связана с различными заболеваниями, однако механизмы, лежащие в основе этих ассоциаций, по-прежнему недостаточно изучены. Одним из потенциальных факторов, способствующих этой взаимосвязи, являются внеклеточные везикли, образующиеся бактериями (БЭМ). Однако обнаружение этих БЭМ сопряжено с трудностями. Поэтому мы предлагаем новый рабочий процесс для выявления бактериальной РНК, присутствующей в циркулирующих внеклеточных везиклах с использованием данных Total EV RNA-seq. В качестве доказательства концепции мы применили этот рабочий поток к набору данных от лиц с

From virtual to reality: innovative practices of digital twins in tumor therapy.

BackgroundAs global cancer incidence and mortality rise, digital twin technology in precision medicine offers new opportunities for cancer treatment.ObjectiveThis study aims to systematically analyze the current applications, research trends, and challenges of digital twin technology in tumor therapy, while exploring future directions.MethodsRelevant literature up to 2024 was retrieved from PubMed, Web of Science, and other databases. Data visualization was performed using R and VOSviewer software. The analysis includes the research initiation and trends, funding models, global research distri

MicroRNAs and Chinese Medicinal Herbs: New Possibilities in Cancer Therapy.

In recent decades Chinese medicine has been used worldwide as a complementary and alternative medicine to treat cancer. Plenty of studies have shown that microRNAs (miRNAs) play fundamental roles in many pathological processes, including cancer, while the anti-cancer mechanisms of Chinese medicinal herbs targeting miRNAs also have been extensively explored. Our previous studies and those of others on Chinese medicinal herbs and miRNAs in various cancer models have provided a possibility of new cancer therapies, for example, up-regulating the expression of miR-23a may activate the positive regu

Совпадение в полном тексте источника
… Introduction With the rapid development of the Human Genome Project, the non-coding sequence that accounts for 99% of the total human genome is attracting more and more attention by researchers. …

Анализ многократной миеломы (ММ) и Моноклональной гаммопатии неопределенных знаков (MGUS)

История семьи является известным фактором риска для множественной миеломы (ММ) и ее предшественника, моноколональной гаммопатии неопределённого значения (МГУС). Предыдущие исследования в рамках всей ассоциации генома (ОСГ) выявили 35 общие loci, связанные с риском MM и 21 связанные с MGS. Цель этого исследования заключалась в выявлении менее распространенных и редких генетических loci, предвосхищающих MM/MGUS, путем проведения анализа последовательности связей на основе целых экспозиций (WES).МЕТОДЫ: Мультиточечный анализ связей был проведен с использованием многоточечного двигателя быстрого с

A call for the United States to continue investing in science.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Year | Development a | Outcome 1990–2003 | Human Genome Project | Personalized medicine (e.g. targeted therapies for breast cancer, including HER2 inhibitors like Herceptin, and chronic myeloid leukemia [Gleevec]) 1990–present | Targeted cancer therapies | Immunotherapy (e.g. checkpoint inhibitors like …

A call for the United States to continue investing in science.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Year | Development a | Outcome 1990–2003 | Human Genome Project | Personalized medicine (e.g. targeted therapies for breast cancer, including HER2 inhibitors like Herceptin, and chronic myeloid leukemia [Gleevec]) 1990–present | Targeted cancer therapies | Immunotherapy (e.g. checkpoint inhibitors like …

Identification of Plasma Protein Biomarkers and Drug Targets for Hematologic Malignancies by Proteome-wide Mendelian Randomization.

Background: It has been reported that the proteome in blood was an important source for biomarker and therapeutic target discovery. However, up to now, few proteomes have been identified with the risk of hematologic malignancies. Methods: Genome-wide association studies (GWASs) including 3,083 plasma proteins are based on data from 54,219 people in the UK Biobank Pharma Proteomics Project (UKB-PPP) and 35,559 individuals from Iceland (deCODE). Genetic correlations with 33 hematologic malignancies were derived from the FinnGen cohort and the UK Biobank Data. Further studies, including Bayesian

Genetic and Plasma Proteomic Approaches to Identify Therapeutic Targets for Graves' Disease and Graves' Ophthalmopathy.

BackgroundThe blood proteome is a major source of biomarkers and therapeutic targets. We aimed to identify the causal proteins and potential targets for Graves' disease (GD) and Graves' ophthalmopathy (GO) via systematic genetic analyses.MethodsGenome-wide association studies (GWASs) on the UK Biobank- Pharma Proteomics Project (UKB-PPP) collected 2923 Olink proteins from 54,219 participants. We conducted a proteome-wide Mendelian randomization (MR) study with cis-pQTLs to identify candidate proteins for GD and GO risk. Colocalization analysis and the Heidi test were used to examine whether th

A call for the United States to continue investing in science.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Year | Development a | Outcome 1990–2003 | Human Genome Project | Personalized medicine (e.g. targeted therapies for breast cancer, including HER2 inhibitors like Herceptin, and chronic myeloid leukemia [Gleevec]) 1990–present | Targeted cancer therapies | Immunotherapy (e.g. checkpoint inhibitors like …

Development of a machine learning-based predictive risk model combining fatty acid metabolism and ferroptosis for immunotherapy response and prognosis in prostate cancer.

Prostate cancer (PCa) remains a leading cause of cancer-related mortality, necessitating robust prognostic models and personalized therapeutic strategies. This study integrated bulk RNA sequencing, single-cell RNA sequencing (scRNA-seq), and spatial transcriptomics to construct a prognostic model based on genes shared between ferroptosis and fatty acid metabolism (FAM). Using the TCGA-PRAD dataset, we identified 73 differentially expressed genes (DEGs) at the intersection of ferroptosis and FAM, of which 19 were significantly associated with progression-free survival (PFS). A machine learning-

Application of the CRISPR/Cas9-based gene editing technique in basic research, diagnosis, and therapy of cancer.

The 2020 Nobel Prize in Chemistry was awarded to Emmanuelle Charpentier and Jennifer Doudna for the development of the Clustered regularly interspaced short palindromic repeats/CRISPR-associated nuclease9 (CRISPR/Cas9) gene editing technology that provided new tools for precise gene editing. It is possible to target any genomic locus virtually using only a complex nuclease protein with short RNA as a site-specific endonuclease. Since cancer is caused by genomic changes in tumor cells, CRISPR/Cas9 can be used in the field of cancer research to edit genomes for exploration of the mechanisms of t

Impact of germline predisposition genes to hematologic malignancies on transplant outcomes and donor selection.

INTRODUCTION: Germline predisposition gene mutations may influence outcomes in patients undergoing hematopoietic stem cell transplantation (HSCT). METHODS: This retrospective study of 558 patients undergoing HSCT (allo-HSCT in 557 cases, auto-HSCT in 1 case) evaluated the impact of germline predisposition gene mutations on outcomes. RESULTS: Enrichment of HAVCR2 mutations in B-NHL and UNC13D mutations in MDS was associated with poorer prognosis. While homozygous mutation carriers (7.5%) overall did not have reduced survival, their outcomes were significantly better with unrelated versus rela

A call for the United States to continue investing in science.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Year | Development a | Outcome 1990–2003 | Human Genome Project | Personalized medicine (e.g. targeted therapies for breast cancer, including HER2 inhibitors like Herceptin, and chronic myeloid leukemia [Gleevec]) 1990–present | Targeted cancer therapies | Immunotherapy (e.g. checkpoint inhibitors like …

A call for the United States to continue investing in science.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Year | Development a | Outcome 1990–2003 | Human Genome Project | Personalized medicine (e.g. targeted therapies for breast cancer, including HER2 inhibitors like Herceptin, and chronic myeloid leukemia [Gleevec]) 1990–present | Targeted cancer therapies | Immunotherapy (e.g. checkpoint inhibitors like …

A call for the United States to continue investing in science.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Year | Development a | Outcome 1990–2003 | Human Genome Project | Personalized medicine (e.g. targeted therapies for breast cancer, including HER2 inhibitors like Herceptin, and chronic myeloid leukemia [Gleevec]) 1990–present | Targeted cancer therapies | Immunotherapy (e.g. checkpoint inhibitors like …

A call for the United States to continue investing in science.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Year | Development a | Outcome 1990–2003 | Human Genome Project | Personalized medicine (e.g. targeted therapies for breast cancer, including HER2 inhibitors like Herceptin, and chronic myeloid leukemia [Gleevec]) 1990–present | Targeted cancer therapies | Immunotherapy (e.g. checkpoint inhibitors like …